Followed Journals
Journal you Follow: 0
 
Sign Up to follow journals, search in your chosen journals and, optionally, receive Email Alerts when new issues of your Followed Journals are published.
Already have an account? Sign In to see the journals you follow.
Similar Journals
Journal Cover
Nature Reviews Drug Discovery
Journal Prestige (SJR): 10.106
Citation Impact (citeScore): 10
Number of Followers: 404  
 
  Full-text available via subscription Subscription journal
ISSN (Print) 1474-1776 - ISSN (Online) 1474-1784
Published by NPG Homepage  [138 journals]
  • Advances in therapeutic peptides targeting G protein-coupled receptors
    • Nature Reviews Drug Discovery, Published online: 19 March 2020; doi:10.1038/s41573-020-0062-z

      Many G protein-coupled receptors (GPCRs) have endogenous peptide agonists, and modifying the sequence of these peptides has led to some successful therapeutics. In this Review, Davenport and colleagues discuss strategies to generate effective GPCR-targeted peptide therapeutics by introducing chemical novelty, extending plasma half-life, improving a therapeutic’s drug-like properties or generating biased ligands. These approaches could overcome some of the challenges in developing peptide therapeutics.Nature Reviews Drug Discovery, Published online: 2020-03-19; doi:10.1038/s41573-020-0062-z2020-03-19
      DOI: 10.1038/s41573-020-0062-z
       
  • Stemming the tide of drug resistance in cancer
    • Nature Reviews Drug Discovery, Published online: 18 March 2020; doi:10.1038/d41573-020-00050-y

      Drug-tolerant persisters, de novo mutations and pre-existing resistance are just some of the ways cancers evade the effects of anti-cancer drugs. Can new targets and new dosing strategies tackle evolutionary forces directly to delay the inevitable?Nature Reviews Drug Discovery, Published online: 2020-03-18; doi:10.1038/d41573-020-00050-y2020-03-18
      DOI: 10.1038/d41573-020-00050-y
       
  • Can anti-inflammatory strategies light up the dim depression pipeline'
    • Nature Reviews Drug Discovery, Published online: 18 March 2020; doi:10.1038/d41573-020-00049-5

      J&J's phase II trial of an immunomodulator for depression could inform the development of stratified medicine in psychiatry.Nature Reviews Drug Discovery, Published online: 2020-03-18; doi:10.1038/d41573-020-00049-52020-03-18
      DOI: 10.1038/d41573-020-00049-5
       
  • Ted W. Love
    • Nature Reviews Drug Discovery, Published online: 16 March 2020; doi:10.1038/d41573-020-00048-6

      In 2013, Ted W. Love — a former drug developer at Onyx, Genentech and elsewhere and cardiologist by training — came out of retirement to take on sickle cell disease. This inherited blood disorder, in which sickled red blood cells clump together, blocking blood flow and the delivery of oxygen through the body, afflicts nearly 100,000 people in the USA and millions more throughout the world. And yet, until recently, these patients have had few therapeutic options for preventing the organ damage, risk of stroke and severe pain associated with disease. Last year, as CEO of Global Blood Therapeutics, Love secured an FDA approval for his company’s voxelotor, a first-in-class anti-sickling agent that at last takes aim at the underlying pathophysiology of the disease. He spoke with Asher Mullard about the science of voxelotor, his hopes of being able to turn sickle cell disease into a quiescent condition and the FDA’s embrace of surrogate end points in more and more indications.Nature Reviews Drug Discovery, Published online: 2020-03-16; doi:10.1038/d41573-020-00048-62020-03-16
      DOI: 10.1038/d41573-020-00048-6
       
  • Upcoming market catalysts in Q2 2020
    • Nature Reviews Drug Discovery, Published online: 16 March 2020; doi:10.1038/d41573-020-00039-7

      Upcoming market catalysts in Q2 2020Nature Reviews Drug Discovery, Published online: 2020-03-16; doi:10.1038/d41573-020-00039-72020-03-16
      DOI: 10.1038/d41573-020-00039-7
       
  • Author Correction: Next-generation influenza vaccines: opportunities and
           challenges
    • Nature Reviews Drug Discovery, Published online: 13 March 2020; doi:10.1038/s41573-020-0066-8

      Author Correction: Next-generation influenza vaccines: opportunities and challengesNature Reviews Drug Discovery, Published online: 2020-03-13; doi:10.1038/s41573-020-0066-82020-03-13
      DOI: 10.1038/s41573-020-0066-8
       
  • Top companies and drugs by sales in 2019
    • Nature Reviews Drug Discovery, Published online: 13 March 2020; doi:10.1038/d41573-020-00047-7

      Top companies and drugs by sales in 2019Nature Reviews Drug Discovery, Published online: 2020-03-13; doi:10.1038/d41573-020-00047-72020-03-13
      DOI: 10.1038/d41573-020-00047-7
       
  • Priority review vouchers miss the policy mark
    • Nature Reviews Drug Discovery, Published online: 11 March 2020; doi:10.1038/d41573-020-00045-9

      Priority review vouchers miss the policy markNature Reviews Drug Discovery, Published online: 2020-03-11; doi:10.1038/d41573-020-00045-92020-03-11
      DOI: 10.1038/d41573-020-00045-9
       
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
 


Your IP address: 3.235.77.252
 
Home (Search)
API
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-